Investment banks JPMorgan and Goldman Sachs are co-lead underwriters of Kythera's initial public offering.
Kythera Biopharmaceuticals, a US-based developer of aesthetic medicines backed by two law firms, has filed for an $86.25m flotation on the Nasdaq stock exchange.
Investment banks JPMorgan and Goldman Sachs are co-lead underwriters of Kythera’s initial public offering.
The company reports a $13m net loss in 2011 on about $11m in income.
Kythera closed its $37.4m series D round of financing in September last year from a pool of investors including Foley Ventures, the corporate venturing unit of…
